Drug Profile
Research programme: oral nucleoside analogues - Pharmasset
Alternative Names: Nucleos(t)ide analogue polymerase inhibitors - Pharmasset; PSI-352666; PSI-352879; PSI-353661; PSI-6206; PSI-6206 monophosphate; PSI-6206 phosphate; PSI-6206 triphosphate; PSI-661; PSI-879Latest Information Update: 02 Feb 2012
Price :
$50
*
At a glance
- Originator Pharmasset
- Class Nucleosides; Nucleotides; Purine nucleotides; Pyrimidine nucleotides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C; HIV infections
Most Recent Events
- 02 Feb 2012 No development reported - Preclinical for Hepatitis C in USA (PO)
- 02 Feb 2012 No development reported for HIV infections in USA (PO)
- 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences